Date | Price Target | Rating | Analyst |
---|---|---|---|
7/30/2024 | $22.00 | Neutral → Sell | BTIG Research |
7/30/2024 | $30.00 → $23.00 | Neutral → Sell | Citigroup |
5/7/2024 | Outperform → Perform | Oppenheimer | |
5/7/2024 | $45.00 → $25.00 | Overweight → Equal Weight | Wells Fargo |
4/3/2024 | $38.00 | Sell → Neutral | Citigroup |
12/5/2023 | $40.00 → $49.00 | Equal Weight → Overweight | Wells Fargo |
11/14/2023 | $50.00 | Buy | CL King |
8/24/2023 | $44.00 | Equal-Weight → Underweight | Morgan Stanley |
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
BTIG Research downgraded Integra from Neutral to Sell and set a new price target of $22.00
Citigroup downgraded Integra from Neutral to Sell and set a new price target of $23.00 from $30.00 previously
Oppenheimer downgraded Integra from Outperform to Perform
PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer will present at the Morgan Stanley Healthcare conference on September 6, 2024 at 10:45am ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at https://investor.integralife.com/events-and-presentations. About Integra LifeSciencesAt Integra LifeSciences, we are driven by our purpose of restoring patients' lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and re
PRINCETON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, announced today that Lea Knight, chief financial officer, will present at the Wells Fargo Healthcare conference on September 4, 2024 at 1:30pm ET. A live webcast of the presentation will be available on the Integra LifeSciences investor relations website at https://investor.integralife.com/events-and-presentations. About Integra LifeSciencesAt Integra LifeSciences, we are driven by our purpose of restoring patients' lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regen
PRINCETON, N.J., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Company (NASDAQ:IART), a leading global medical technology company, today issued its latest Environmental, Social and Governance (ESG) report. The report highlights the company's 2023 ESG performance and ongoing efforts against the ESG strategy and roadmap established three years ago. "Innovating treatment pathways to advance patient outcomes and set new standards of care is work that matters to our Integra colleagues around the world and is what drives us each and every day," said Jan De Witte, president and chief executive officer, Integra LifeSciences. "We are pleased with the advances we have made to mee
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)
10-Q - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
SD - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)
SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)
SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)
SC 13G/A - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Subject)
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2024. Second Quarter 2024 Highlights Second quarter revenues of $418.2 million increased 9.7% on a reported basis and 2.3% on an organic basis compared to the prior year. Revenue increased 0.3% on an organic basis excluding Boston.Second quarter GAAP earnings per diluted share of $(0.16), compared to $0.05 in the prior year; adjusted earnings per diluted share of $0.63, compared to $0.71 in the prior year.Early integration success with the Acclarent ENT a
PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release second quarter 2024 financial results on Monday, July 29, 2024, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the co
PRINCETON, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2024. First Quarter 2024 Highlights First quarter revenues of $368.9 million declined 3.1% on a reported basis and declined 2.5% on an organic basis compared to the prior year. Revenue increased 1.6% on an organic basis excluding BostonFirst quarter GAAP earnings per diluted share of $(0.04), compared to $0.29 in the prior year; adjusted earnings per diluted share of $0.55, compared to $0.74 in the prior yearCompleted the acquisition of the Acclarent, Inc. on April 1
Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:IART) with a Hold and raises the price target from $25 to $32.
In the last three months, 8 analysts have published ratings on Integra Lifesciences (NASDAQ:IART), offering a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 4 3 0 Last 30D 0 0 0 1 0 1M Ago 0 0 1 0 0 2M Ago 0 0 1 0 0 3M Ago 0 1 2 2 0 The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $28.12, a high estimate of $40.00, and a low estimate of $24.00. A decline of 21.34% from
Morgan Stanley analyst Drew Ranieri maintains Integra Lifesciences (NASDAQ:IART) with a Underweight and raises the price target from $24 to $27.
Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera
NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S
PRINCETON, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that Jeff Graves, Ph.D., president and chief executive officer of 3D Systems Corporation, was appointed to the company's board of directors, effective immediately. With the appointment of Dr. Graves, Integra has added four new directors since 2021. "I am pleased to welcome Jeff to our board of directors. He is a highly-accomplished executive with a track record of leading and transforming technically complex businesses," said Stuart Essig, chairman of the Integra board of directors. "His experience in streamlining global